Evidence map›Paper›PMID 35462932›Full record

ArticleFrontiers in pharmacology2022

Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab.

Luisa Ricciardi, Daniel Griscti Soler, Alessandra Bennici, Silvia Brunetto, Giovanni Pioggia, Sebastiano Gangemi

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Immunological Markers Associated with Skin Manifestations of EGPA.International journal of molecular sciences · 2025
    Observational
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Luisa RicciardiDepartment of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, Policlinico "G. Martino", University of Messina, Messina, Italy.
Daniel Griscti SolerDepartment of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, Policlinico "G. Martino", University of Messina, Messina, Italy.
Alessandra BenniciDepartment of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, Policlinico "G. Martino", University of Messina, Messina, Italy.
Silvia BrunettoDepartment of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, Policlinico "G. Martino", University of Messina, Messina, Italy.
Giovanni PioggiaInstitute for Biomedical Reasearch and Innovation, National Research Council of Italy (IRIB-CNR), Messina, Italy.
Sebastiano GangemiDepartment of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, Policlinico "G. Martino", University of Messina, Messina, Italy.
University of Messina · ITInstitute for Biomedical Research and Innovation · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

asthmabenralizumabEGPAeosinophilsyoung adult

Identifiers

PMID35462932
PMCPMC9022602
OpenAlexW4225912389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.